|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Assembly Biosciences, Inc.
| | | Phone: | (855) 971-4467 | Year Established: | 2005 | Ticker: | ASMB | Exchange: | NASDAQ | Main Contact: | Derek Small, CEO | | Other Contacts: | Jackie Papkoff, PhD, Senior VP, CSO Microbiome Micah Mackison, VP, Corporate Development & Strategy Hongmei Huang, Ph.D., VP, Information Technology & Informatics Wayne Herber, Ph.D., VP, Biological Manufacturing and Quality Elizabeth Haber Lacy, General Counsel Uri Lopatin, MD, CMO Richard Colonno, Ph.D., CSO Graham Cooper, CFO & COO
| | Company Description | Assembly Biosciences (formerly Ventrus BioSciences) is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly's HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. | |
|
|
|
|
|